Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04303845 · ClinicalTrials.gov registry record · Phase 2
Erenumab For Treatment of Hemicrania Continua
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04303845: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT04303845 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04303845, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.
Primary Outcome
The total number of days per month (28 days) with headache of any kind/severity
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 2 |
Why NCT04303845 stopped before completion
NCT04303845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT04303845 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04303845 about?
NCT04303845 is a clinical study titled "Erenumab For Treatment of Hemicrania Continua". This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals being treated for hemicrania continua.
What is the current status of trial NCT04303845?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-08-04. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04303845?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT04303845?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04303845's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI